Rx costs driving up US Medigap premiums

13 February 2001

Rising costs of US Medigap health care policies, which top uptraditional Medicare coverage, are forcing many elderly and disabled people out of the programs, and it is the prescription drug component that is driving the premium increases, reports the New York Times.

Empire HealthChoice, the largest Medigap drug insurer, says it is raising its premiums 31% on March 1 for policies with drug coverage. The company said it had underestimated rising medical costs, even after 10% premium rises in each of the last two years, and adds that it lost $18 million on Medigap drug policies last year, notes the NYT.

The report adds that the National Association of Insurance Commissioners is considering a revision of Medigap, and one proposal being examined is to make all Medigap plans include prescription drug coverage.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight